viewIQ-AI Limited

IQ-AI imaging arm working on technologies that lessen reliance on potentially harmful chemicals

Ultimately, Imaging Biometrics hopes its advances eliminate gadolinium-based contrast agents altogether

The race to find alternatives appears to be a well-timed one given the latest welter of clinical evidence linking these gadolinium products with a host of conditions

IQ-AI Limited (LON:IQAI) said its Imaging Biometrics (IB) arm is continuing to develop products that reduce and ultimately eliminate gadolinium-based contrast agents in medical imaging.

Its race to find alternatives appears to be a well-timed one given the latest welter of clinical evidence linking these gadolinium products with a host of conditions.

Included on that list is nephrogenic systemic fibrosis, a rare disease which leads to skin contractures. Other side-effects include bone and brain deposits; rashes and aching joints.

IB has been working on a portfolio of products that cut down on the use of gadolinium with the aim, longer term, of finding alternatives to the element.

It currently offers two methods that eliminate the "pre-load" dose of traditional gadolinium-based contrast agents (GBCA), which significantly reduces the exposure to the potentially harmful chemicals – the products are Dual Echo and Low Flip Angle.

And IB is working on a technology called simulated T1+C that would generate results almost identical to a post-contrast image but without the use of a contrast agent.  Simulated T1+C version 2.0 is the firm’s zero GBCA product.

IQ-AI chief executive Trevor Brown said: "[We are] committed to lowering the GBCA doses used for all populations, but particularly those most vulnerable to gadolinium deposition disease.

“The gadolinium free imaging project, if successful, will have a significant impact on the revenues of the company over coming years. We will continue to update shareholders as matters progress."

In lunchtime trading, shares in IQ-AI were 0.6% higher at 4.45p.

 -- Adds share price --

Quick facts: IQ-AI Limited

Price: 4.15 GBX

Market: LSE
Market Cap: £5.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...



Full interview: More from Imaging Biometrics on the AI deal

IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant. Under the agreement with US firm AI...

1 week, 3 days ago

2 min read